Highlighting a year of conference coverage for ACT.
Over the past few weeks, signs of 2023 coming to an end are aplenty; the temperatures have fallen, and holidays are beginning to appear more frequently on the calendar. I’m sure I’m not alone in feeling that the end of each year serves as a good time to reflect on the previous 12 months. For Applied Clinical Trials, there have been many bright spots throughout 2023. One in particular I’d like to highlight here is our conference coverage—a pillar of our many brands at MJH Life Sciences®. ACT was front and center at several of this year's largest industry conferences, including the Summit for Clinical Ops Executives (SCOPE) North America, SCOPE Europe (see our executive roundtable from the event here), DPHARM, and the DIA Annual Meeting. Our editors did a fantastic job in providing timely coverage of breakout sessions and speaking with industry leaders for video interviews. All of the content can be found here on our website:
www.appliedclinicaltrialsonline.com/latest-conference. We look forward to continuing our coverage of these events in 2024.
Not to be overlooked, of course, are present happenings. For this December issue of ACT, we focus on novel clinical trial designs. From basket trials, to using real-world evidence (RWE), and master protocols, there are many new elements to trial design. We explore some of these design approaches and how regulatory authorities are moving the needle on their acceptance.
Our first feature examines the benefits of early protocol assessment in boosting patient centricity. For example, with so many new design elements in the fold, getting ahead of potential pitfalls can greatly reduce patient burden while expanding opportunities to apply clinical data on a wider scale.
Following is a feature looking at innovation in clinical trials for chimeric antigen receptor (CAR) T-cell therapies. These products have steadily demonstrated positive results for oncology patients in recent years. The article focuses on next-step, digitally driven pursuits for CAR T-cell trials and how this area can be advanced further. Our final December feature discusses strategies for implementing digital protocols and ways to streamline processes such as content reuse, workflow animation, and study design.
As always, thank you for reading.
Mike Hennessy Jr, president and CEO, MJH Life Sciences®
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.